Literature DB >> 20856941

Profiling small molecule inhibitors against helix-receptor interactions: the Bcl-2 family inhibitor BH3I-1 potently inhibits p53/hDM2.

Jason R Porter1, Mark R Helmers, Ping Wang, Jennifer L Furman, Stephen T Joy, Paramjit S Arora, Indraneel Ghosh.   

Abstract

We validate a practical methodology for the rapid profiling of small molecule inhibitors of protein-protein interactions. We find that a well known BH3 family inhibitor can potently inhibit the p53/hDM2 interaction.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20856941      PMCID： PMC4576826          DOI： 10.1039/c0cc02969f

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  32 in total

1.  Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL.

Authors:  A Degterev; A Lugovskoy; M Cardone; B Mulley; G Wagner; T Mitchison; J Yuan
Journal:  Nat Cell Biol       Date:  2001-02       Impact factor: 28.824

Review 2.  Fluorescence polarization and anisotropy in high throughput screening: perspectives and primer.

Authors:  J C Owicki
Journal:  J Biomol Screen       Date:  2000-10

3.  Enhanced metabolic stability and protein-binding properties of artificial alpha helices derived from a hydrogen-bond surrogate: application to Bcl-xL.

Authors:  Deyun Wang; Wei Liao; Paramjit S Arora
Journal:  Angew Chem Int Ed Engl       Date:  2005-10-14       Impact factor: 15.336

4.  Miniature protein inhibitors of the p53-hDM2 interaction.

Authors:  Joshua A Kritzer; Reena Zutshi; Mingtatt Cheah; F Ann Ran; Rachel Webman; Taritree M Wongjirad; Alanna Schepartz
Journal:  Chembiochem       Date:  2006-01       Impact factor: 3.164

5.  Inhibition of beta-amyloid fibrillization by directed evolution of a beta-sheet presenting miniature protein.

Authors:  Thaddeus J Smith; Cliff I Stains; Scott C Meyer; Indraneel Ghosh
Journal:  J Am Chem Soc       Date:  2006-11-15       Impact factor: 15.419

Review 6.  BCL-2 family antagonists for cancer therapy.

Authors:  Guillaume Lessene; Peter E Czabotar; Peter M Colman
Journal:  Nat Rev Drug Discov       Date:  2008-12       Impact factor: 84.694

7.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

Authors:  Christin Tse; Alexander R Shoemaker; Jessica Adickes; Mark G Anderson; Jun Chen; Sha Jin; Eric F Johnson; Kennan C Marsh; Michael J Mitten; Paul Nimmer; Lisa Roberts; Stephen K Tahir; Yu Xiao; Xiufen Yang; Haichao Zhang; Stephen Fesik; Saul H Rosenberg; Steven W Elmore
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

8.  Oligomerization domain-directed reassembly of active dihydrofolate reductase from rationally designed fragments.

Authors:  J N Pelletier; F X Campbell-Valois; S W Michnick
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

9.  Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening.

Authors:  I J Enyedy; Y Ling; K Nacro; Y Tomita; X Wu; Y Cao; R Guo; B Li; X Zhu; Y Huang; Y Q Long; P P Roller; D Yang; S Wang
Journal:  J Med Chem       Date:  2001-12-06       Impact factor: 7.446

Review 10.  Targeting the cancer kinome through polypharmacology.

Authors:  Zachary A Knight; Henry Lin; Kevan M Shokat
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716
View more
  3 in total

Review 1.  Split-protein systems: beyond binary protein-protein interactions.

Authors:  Sujan S Shekhawat; Indraneel Ghosh
Journal:  Curr Opin Chem Biol       Date:  2011-11-07       Impact factor: 8.822

2.  Engineering bacterial transcription regulation to create a synthetic in vitro two-hybrid system for protein interaction assays.

Authors:  Ying Zhou; Haruichi Asahara; Nils Schneider; Patricia Dranchak; James Inglese; Shaorong Chong
Journal:  J Am Chem Soc       Date:  2014-09-26       Impact factor: 15.419

Review 3.  Structural insights into the transcription-independent apoptotic pathway of p53.

Authors:  Seung-Wook Chi
Journal:  BMB Rep       Date:  2014-03       Impact factor: 4.778
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.